Dynamic monitoring of serum tumor markers as prognostic factors in patients with advanced non-small-cell lung cancer treated with first-line immunotherapy: a multicenter retrospective study.,Therapeutic Advances in Medical Oncology

当前位置： X-MOL 学术 › Ther. Adv. Med. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Dynamic monitoring of serum tumor markers as prognostic factors in patients with advanced non-small-cell lung cancer treated with first-line immunotherapy: a multicenter retrospective study.
Therapeutic Advances in Medical Oncology ( IF 4.9 ) Pub Date : 2023-10-31 , DOI: 10.1177/17588359231206282
Xiongwen Yang _{1,

2} , Yi Xiao ₃ , Yubin Zhou ₃ , Huiyin Deng ₄ , Zihao Yuan ₅ , Longyan Dong ₅ , Jun Lan ₆ , Hao Hu ₇ , Jian Huang ₈ , Shaohong Huang ₉

Affiliation

Department of Thoracic Surgery, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China.
School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
Department of Cardio-Thoracic Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Department of Anesthesiology, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
The Second Clinical Medical College of Guangdong Medical University, Dongguan, Guangdong, China.
Department of General Surgery, the People's Hospital of Gaoan City. Gaoan, Jiangxi, China.
Department of Radiation Therapy, General Hospital of Southern Theater Command, Guangzhou, Guangdong 510000, China.
Department of Thoracic Surgery, Jiangxi Cancer Hospital, Nanchang, Jiangxi 330029, China.
Department of Cardio-Thoracic Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510000, China.

Background To date, no specific studies have reported the use of dynamic serum tumor markers (STMs) as prognostic factors in patients with advanced non-small-cell lung cancer (NSCLC) who receive first-line immunotherapy. Therefore, it is unclear whether STMs can be used as a prognostic factor for first-line immunotherapy in advanced NSCLC. Objectives To elucidate the role of STMs in monitoring immunotherapy response in advanced NSCLC. Patients were treated with first-line programmed cell death-1/programmed cell death ligand-1 inhibitors at four Chinese centers. Design This was a multicenter retrospective study. Methods Blood samples were collected at baseline and after 6-8 weeks of treatment. Computed tomography scans were used to evaluate treatment efficacy according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Post-treatment drops in STMs [Serum carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), cytokeratin fragment 19 (CYFRA21-1), carbohydrate antigen 19-9 (CA19-9), and carbohydrate antigen 125 (CA125)] were decreased ⩾20% (Group C) over baseline was used as cutoff level for defining a marker response. If STMs were increased by ⩾20% after treatment, the therapeutic effect was limited (Group A). Patients with STM changes between a 20% increase or decrease were enrolled in Group B. In univariate and multivariate stepwise Cox regression analyses, STMs and RECIST responses were analyzed for their impact on progression-free survival (PFS) and overall survival (OS). Results The analysis included 716 patients. By multivariate analysis, CEA, NSE, CYFRA21-1, CA19-9, and CA125 (Group A versus Group B and Group A versus Group C) were associated with significant differences in PFS. Similar results were observed in the OS analysis. Similar results were observed in the adenocarcinoma subgroup analyses. In squamous cell carcinoma subgroup analyses, there was no statistical difference in PFS (p = 0.147) or OS (p = 0.068) between Group A and Group B for CA125. Conclusion The increase and decrease in serum levels of STMs might be reliable prognostic factors for immunotherapy efficacy in NSCLC patients.

更新日期：2023-10-31

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>